GlassScriptPhysician profile
Christopher Robin Cornett
NPI 1952863573
$10,853.95
in general payments reported to CMS, 2019-2025
33 companies · $3,597 in 2025
The $3,597 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,529 · 2023: $3,040 · 2024: $2,687 · 2025: $3,597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,220 · Education: $65.73 · Consulting Fee: $39.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,219.51 |
| Education | $65.73 |
| Consulting Fee | $39.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,611.38 | 2022-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $1,459.08 | 2022-2025 | Fasenra, Tezspire, Airsupra |
| Amgen INC. | $1,130.02 | 2022-2025 | Tezspire, Actimmune |
| Regeneron Healthcare Solutions, INC. | $1,047.75 | 2022-2025 | Dupixent |
| Genzyme Corporation | $1,043.48 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $666.64 | 2022-2025 | |
| Alk-Abello, INC | $596.23 | 2022-2025 | Odactra, Grastek, Ragwitek |
| Pfizer INC. | $402.35 | 2022-2025 | |
| Blueprint Medicines Corporation | $389.53 | 2022-2025 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $380.86 | 2022-2025 | Cuvitru, Takhzyro |
| Biocryst US Sales Co., LLC | $307.16 | 2023-2025 | Orladeyo |
| Genentech USA, INC. | $200.52 | 2024-2025 | Xolair |
| Ionis Pharmaceuticals, INC. | $169.11 | 2025 | Dawnzera |
| Csl Behring | $165.38 | 2022-2025 | Hizentra, Andembry |
| Optinose US, INC. | $164.05 | 2022-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $147.47 | 2022-2024 | |
| Grifols USA, LLC | $119.04 | 2022-2025 | Xembify |
| Octapharma USA, INC. | $108.48 | 2023-2025 | Cutaquig, Panzyga, Octagam Immune Globulin (Human) |
| Lilly USA, LLC | $89.03 | 2024-2025 | Ebglyss |
| Abbvie INC. | $86.07 | 2022-2023 | |
| Kaleo, INC. | $84.28 | 2022-2023 | Auvi-Q |
| Incyte Corporation | $83.42 | 2022-2025 | Opzelura |
| Ars Pharmaceuticals Operations, INC. | $74.50 | 2025 | Neffy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.13 | 2022 | |
| Pharming Healthcare, INC. | $40.73 | 2024 | Ruconest |
| Adma Biomanufacturing LLC | $39.32 | 2023 | |
| Arcutis Biotherapeutics, INC. | $38.84 | 2025 | Zoryve |
| Hikma Pharmaceuticals USA | $36.08 | 2023-2024 | Ryaltris |
| Leo Pharma INC. | $29.88 | 2025 | Adbry |
| Greer Laboratories, INC. | $28.47 | 2025 | Oralair |
| Cycle Pharmaceuticals INC | $24.64 | 2025 | Sajazir |
| Aimmune Therapeutics, INC. | $23.53 | 2022 | |
| Paratek Pharmaceuticals, INC. | $17.50 | 2025 | Xhance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Cornett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.